Abstract:Clinical trials involving systemic neoadjuvant treatments in breast cancer aim to shrink tumors before surgery while simultaneously allowing for controlled evaluation of biomarkers, toxicity, and suppression of distant (occult) metastatic disease. Yet neoadjuvant clinical trials are rarely preceded by preclinical testing involving neoadjuvant treatment, surgery, and post-surgery monitoring of the disease. Here we used a mouse model of spontaneous metastasis occurring after surgical removal of orthotopically implanted primary tumors to develop a predictive mathematical model of neoadjuvant treatment response to sunitinib, a receptor tyrosine kinase inhibitor (RTKI). Treatment outcomes were used to validate a novel mathematical kinetics-pharmacodynamics model predictive of perioperative disease progression. Longitudinal measurements of presurgical primary tumor size and postsurgical metastatic burden were compiled using 128 mice receiving variable neoadjuvant treatment doses and schedules (released publicly at https://zenodo.org/records/10607753). A non-linear mixed-effects modeling approach quantified inter-animal variabilities in metastatic dynamics and survival, and machine-learning algorithms were applied to investigate the significance of several biomarkers at resection as predictors of individual kinetics. Biomarkers included circulating tumor- and immune-based cells (i.e., circulating tumor cells and myeloid-derived suppressor cells) as well as immunohistochemical tumor proteins (i.e., CD31 and Ki67). Our computational simulations show that neoadjuvant RTKI treatment inhibits primary tumor growth but has little efficacy in preventing (micro)-metastatic disease progression after surgery and treatment cessation. Machine learning algorithms that included support vector machines, random forests, and artificial neural networks, confirmed a lack of definitive biomarkers, which shows the value of preclinical modeling studies to identify potential failures that should be avoided clinically. Using simulations from a mechanistic mathematical model compared with preclinical data from surgical metastasis models, we found that anti-tumor effects of neoadjuvant receptor tyrosine kinase inhibitor treatment can differ between the primary tumor and metastases in the perioperative setting. Model simulations with variable drug doses and scheduling of neoadjuvant treatment revealed a contrasting impact on initial primary tumor debulking and metastatic outcomes long after treatment has stopped and the primary tumor has been surgically removed. Using machine-learning algorithms, we identified the limited power of several circulating cellular and molecular biomarkers in predicting metastatic outcomes, uncovering a potential fast-track strategy for assessing future clinical biomarkers by pairing patient studies with identical studies in mice.

Development of an optimized machine learning approach to enhance brain metastatic burden assessment in preclinical models.

Development of an optimized machine learning approach for assessing brain metastatic burden in preclinical models

Innv-02. Brainmets: A Clinician-Friendly Software To Manually Segment Brain Metastases And Detect Primary Tumor Origin Using Deep Learning

Cryo-Imaging and Software Platform for Analysis of Molecular MR Imaging of Micrometastases

Machine-Learning-Aided Prediction of Brain Metastases Development in Non-Small-Cell Lung Cancers

Machine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatment

Risk Classification of Brain Metastases via Radiomics, Delta-Radiomics and Machine Learning

MetFinder: A Tool for Automated Quantitation of Metastatic Burden in Histological Sections From Preclinical Models

From pre-clinical to translational brain metastasis research: current challenges and emerging opportunities

A transformer-based deep learning approach for classifying brain metastases into primary organ sites using clinical whole brain MRI

Comparative analysis of the spatial distribution of brain metastases across several primary cancers using machine learning and deep learning models

Quantitative analysis of metastatic breast cancer in mice using deep learning on cryo-image data

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Preclinical Models of Brain Metastases in Breast Cancer

Multimodal radiomics-based methods using deep learning for prediction of brain metastasis in non-small cell lung cancer with 18F-FDG PET/CT images

In vivo characterization of brain tumor biomechanics: magnetic resonance elastography in intracranial B16 melanoma and GL261 glioma mouse models

BrainMetDetect: Predicting Primary Tumor from Brain Metastasis MRI Data Using Radiomic Features and Machine Learning Algorithms

Dissecting metastasis using preclinical models and methods

Accurate and Early Metastases diagnosis in live animals with Multimodal X-ray and Optical Imaging

Deep learning ensembles for detecting brain metastases in longitudinal multi-modal MRI studies

Prediction of treatment response in patients with brain metastasis receiving stereotactic radiosurgery based on pre-treatment multimodal MRI radiomics and clinical risk factors: A machine learning model